# Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies

Source: https://onco.cc/trials/nct06028074/  
OnCo record `nct06028074` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of GIM122 in advanced solid tumours, run by Georgiamune Inc, now recruiting.

## Summary

Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies is a phase 1/2 interventional study registered as NCT06028074 by Georgiamune Inc, with 111 participants planned, started 2023-12-12 and due to reach its primary completion in 2026-09. Interventions recorded: GIM122.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06028074
- Phase: 1/2
- Setting: A First-in-Human, Open-Label, Phase 1/2 Dose-Escalation With Enrichment and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of GIM-122 as a Single Agent in Adult Subjects With Advanced Solid Malignancies
- Sponsor: Georgiamune Inc
- Enrolled: 111

## Sources

- ClinicalTrials.gov NCT06028074: https://clinicaltrials.gov/study/NCT06028074

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Georgiamune](https://onco.cc/companies/georgiamune/)

---
JSON: https://onco.cc/api/v1/entities/nct06028074.json